- Up to 60% of patients with migraine do not sufficiently respond to triptans.
- Efficacy of celecoxib oral solution in participants with insufficient response to triptans for the acute treatment of migraine: pooled results from a post-hoc analysis of two Phase 3 randomized clinical trials.
- In patients who had an insufficient response to triptans, significantly more patients in the ELYXYB-treated arm achieved 2-hour pain freedom (the gold standard for efficacy endpoint in migraine) than placebo (33.3% vs. 14.3%, p=0.0036). The likelihood of achieving pain freedom was 200% greater with ELYXYB than with placebo (OR=3.0).
Scilex Holding Presents Poster On ELYXYB At The Annual Scientific Meeting Of The AHS To Be Held On June 13-16, 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.